IRF4 instructs effector Treg differentiation and immune suppression in human cancer


The molecular mechanisms responsible for the high immunosuppressive capacity of CD4+ Tregs in tumors are not well known. High-dimensional single-cell profiling of T cells from chemotherapy-naive individuals with non-small-cell lung cancer identified the transcription factor IRF4 as specifically expressed by a subset of intratumoral CD4+ effector Tregs with suppressive superior activity. In contrast to the IRF4− counterparts, IRF4+ Tregs expressed a vast array of suppressive molecules, and their presence correlated with multiple exhausted subpopulations of T cells. Integration of transcriptomic and epigenomic data revealed that IRF4, either alone or in combination with its partner BATF, directly controlled a molecular program responsible for immunosuppression in tumors. Accordingly, deletion of IRF4 exclusively in Tregs resulted in delayed tumor growth in mice while the abundance of IRF4+ Tregs correlated with poor prognosis in patients with multiple human cancers. Thus, a common mechanism underlies immunosuppression in the tumor microenvironment irrespective of the tumor type.

Introduction

Despite recent clinical breakthroughs in adoptive T cell transfer approaches and checkpoint blockade in treating hematopoietic and solid tumors, suppression of the antitumor immune response in the tumor microenvironment (TME) is a major obstacle to tumor regression (1). Although antitumor immune cells, such as T and NK cells, normally infiltrate tumors, and their abundance correlates with better prognosis in certain cancers, the presence of inhibitory populations, such as regulatory CD4+ T cells (Tregs), counteract tumor rejection (2). The main role of Tregs is to maintain immune homeostasis in physiology by inhibiting effector T cells via different modes of action, including expression of cell-surface inhibitors, such as cytotoxic T lymphocyte–associated protein 4 (CTLA-4) (3); production of inhibitory cytokines, such as IL-10 (4), TGF-β (5), or IL-35 (6); depletion of IL-2 by overexpression of the high-affinity IL-2 receptor α chain (IL-2Ra, also known as CD25); purine-mediated suppression by CD39-dependent conversion of ATP (7); or direct cytotoxicity (8), thus preventing autoimmunity and immunopathology (reviewed in Vignali et al., ref. 9). Conversely, Tregs are aberrantly enriched in tumors and dampen antitumor immune responses (10). This detrimental effect on antitumor immunity is demonstrated by a plethora of preclinical data in which systemic Treg depletion or inhibition of their function promotes tumor regression (11–14). Unfortunately, depletion or inhibition of Tregs often results in severe autoimmunity, allergy, and immunopathology (11–14); therefore, new strategies are required to safely deplete Tregs specifically in the TME. The prerequisite to do so is the identification of a specific molecular program or molecules that are exclusively present in tumor-associated Tregs, which would therein allow us to spare circulating Tregs and maintain peripheral homeostasis.

Transcriptional profiling recently revealed that CD4+ Tregs isolated from colon, lung, and breast tumors are transcriptionally different from those isolated from the adjacent tissues and the blood (15, 16). In particular their transcriptional profile overlaps with that of effector Tregs described in mice, which show enhanced suppressive activity. This includes the increased expression of molecules, such as CTLA-4, 4-1BB, CCR8, ICOS, and others (17). Noteworthily, increased expression of CCR8 (15, 16), LAYN, or MAGEH1 (15) by the intratum-
moral Tregs correlated with poor prognosis, suggesting a pivotal role of these cells in inhibiting antitumor immune responses and/or favoring tumor growth.

The molecular mechanisms leading to increased Treg activity in tumors remain ill-defined. Studies performed over the last decade have elucidated in part the transcriptional network at the basis of murine effector Treg differentiation in lymphoid and nonlymphoid tissues. Once activated, Tregs undergo a program of effector differentiation that mirrors Th cell differentiation by expressing transcription factors (TFs) that regulate Th polarization, such as T-bet, GATA-3, or Bcl-6 (17). Additional TFs might be involved in regulating effector Tregs at specific tissue sites, such as PPARY, which controls the unique transcriptional and metabolic signature of those cells residing in the visceral adipose tissue (18). Interferon regulatory factor 4 (IRF4), initially identified as the TF responsible for the generation of those Tregs specific for the Treg phenotype, plays a central role in determining the Treg transcriptional program, functionality, and regulation of antitumor immunity remains completely unexplored.

Here, we reported the existence of 2 subsets of tumor-infiltrating Tregs with differential expression of IRF4, as revealed by high-dimensional single-cell analysis of lung, liver, and melanoma-infiltrating T cells. IRF4 defined activated effector Tregs with enhanced suppressive activity, the abundance of which correlates with poor prognosis in multiple human cancers. Consistent with a direct requirement for IRF4 for the enhanced suppressive functions, deletion of Irf4 in Tregs enhanced antitumor immunity in a mouse model of cancer in vivo. We further identified a core network of immunosuppressive genes directly regulated by IRF4 in interaction with its molecular partner, BATF, thereby demonstrating that IRF4 instructs the suppressive activity of Tregs in human cancer.

Results

Treg heterogeneity in the TME and its relation to IRF4. To gain insight into CD4+ T cell phenotypes at the tumor site, we initially investigated T cells in a cohort of 53 patients with NSCLC (Supplemental Table 1 and ref. 24; supplemental material available online with this article; https://doi.org/10.1172/JCI130426DS1) with a 27-parameter polychromatic flow cytometry panel encompassing markers of memory and effector T cell differentiation, activation, metabolic activity, and exhaustion as well as Treg markers (Supplemental Table 2). We profiled tumors (n = 53), paired adjacent cancer-free lung tissues (n = 45), and peripheral blood samples (PB; n = 22) of treatment-naive patients (Supplemental Table 1). We next used Uniform Manifold Approximation and Projection (UMAP), a dimensionality reduction visualization approach that preserves the local and the global structure of single-cell data, to simplify the visualization of marker coexpression in a 2D space (Figure 1, A and B). Overall, CD4+ T cells from the 3 body sites displayed a different single-cell profile (Figure 1A). Previously described dynamics aside (24), such as the loss of CD45RA+, CCR7+, and CD27+ (identifying naive and early memory cells) and the accumulation of HLA-DR+ activated and PD1+ T cells, we also noticed the accumulation of CD25+Foxp3+ Tregs expressing the TF IRF4 in tumor versus adjacent lung and blood samples (Figure 1, B–D). Manual gating of flow cytometry data indicated that approximately 40% of CD25+Foxp3+ Tregs in tumors expressed IRF4, while the rest were IRF4+ (Figure 1, C and D), representing Treg heterogeneity at the tumor site. In addition, the majority of conventional CD4+ T (Tconv) cells lacked IRF4 expression (Figure 1, C and D). Flow cytometric analysis also revealed that IRF4+ Tregs retain increased expression of PD1, TIGIT, and TIM3 receptors and CD71 and CD98 metabolic markers compared with both IRF4− Tregs and Tconv cells in tumors (Figure 1E). These markers are generally upregulated with activation. In line with our results, reanalysis of published single-cell RNA-sequencing (scRNA-seq) data (25) of CD4+ tumor-infiltrating lymphocytes from patients with NSCLC identified IRF4 expression as largely confined to a subpopulation of CTLA4hi Tregs (subset 9-CTLAA4; Figure 1F), while it was relatively lower in other cell subsets, including non-activated Tregs (8-FOX3P). CTLA4hi Tregs, which also express FOXP3, displayed an effector signature, including expression of CCR8, ICOS, TNFRSF4 (encoding OX40), TNFRSF9 (encoding CD137/4-1BB), and the IRF4 transcriptional partner BATF. (Figure 1G). We identified a similar subset of IRF4-expressing Tregs by scRNA-seq analysis of CD45+ cells infiltrating hepatocellular carcinoma (Supplemental Figure 1A and ref. 26). Notably, IRF4 expression correlated with multiple Treg genes but not with TFs related to other Th cell subsets in single CD4+ T cells isolated from melanomas (Supplemental Figure 1B and ref. 27). Thus, a common phenotypic and gene expression architecture defines tumor-infiltrating Tregs in multiple human cancers.
IRF4 expression defines effector Tregs with enhanced suppressive potential capable of promoting tumor growth in vivo. We further characterized IRF4⁺ and IRF4⁻ Tregs by bulk RNA-seq. As the intranuclear localization of TFs precluded the isolation of viable cells based on IRF4 expression levels, we used a surrogate surface staining strategy for FACS-based isolation of Treg subsets. Bulk Tregs from tumors, defined as CD25⁺CD127⁻, were further separated according to CCR8 and ICOS to identify IRF4⁺ and IRF4⁻ Tregs (Figure 2A, Supplemental Figure 2A, and Methods). As expected, both of these subsets expressed high levels of FOXP3.

Figure 2. Transcriptional and functional profiling defines the effector and enhanced suppressive nature of IRF4⁺ Tregs. (A) Representative CCR8 and ICOS expression in tumor-infiltrating CD25⁺CD127⁻ Treg subsets defined by IRF4 expression and percentage of IRF4 expression in tumor-infiltrating Tregs gated as CCR8⁺ICOS⁻ or CCR8⁻ICOS⁻. (B) Heatmap of differentially expressed genes (DEGs) in the FACS-sorted CCR8⁺ICOS⁺ versus ICOS⁻CCR8⁻ tumor-infiltrating Tregs, as obtained by RNA-seq (FDR < 0.05). Selected DEGs are indicated. For some genes, protein names are indicated. (C) Hallmark gene sets (MSigDB; as obtained by GSEA) significantly enriched in cells sorted as in B. (D) Transcription factor binding motif (TFBM) enrichment analysis by pScan of RNA-seq data obtained as in B. Colored dots indicate significant hits. (E) CFSE-labeled CD4⁺CD25⁻ T (Tconv) cells dilution from a representative blood sample. Tconv cells were cocultured with Suppression Inspector MACSibead beads and different ratios of intratumoral Treg subsets for 5 days. Data are representative of 5 independent experiments. (F) Tumor volumes in FoxP3EGFP-cre-ERT2(control) (n = 7) or Irf4fl/fl FoxP3EGFP-cre-ERT2 (n = 5) mice following the administration of tamoxifen. Tumor curves in individual mice and mean ± SEM of the same cohort are shown. **P < 0.01, paired Student’s t test.
compared with Tconv cells (Supplemental Figure 2B) and their gene expression significantly overlapped with a tumor-infiltrating Treg signature, as obtained from a NSCLC scRNA-seq data set (ref. 25 and Supplemental Figure 2C), confirming the Treg identity of these subsets.

A multidimensional scaling plot of gene expression profiles showed that sorted intratumoral CCR8+ICOS+ (IRF4+) and CCR8 ICOS− (IRF4−) clustered separately, indicating substantial differences at the transcriptional level (Supplemental Figure 2D). Overall, we identified 2674 differentially expressed genes (DEGs; FDR < 0.05; Supplemental Table 3). CCR8+ICOS+ Tregs expressed high amounts of transcripts encoding molecules involved in effector differentiation (e.g., TNFRSF9, TNFRSF4, TNFRSF18, IL2RA), transcriptional regulation of effector Tregs (BATF), proliferation (MKI67), Treg identity (IKZF2, encoding the TF Helios [ref. 28]), costimulation (ICOS) and suppressive function (CTLA4). Additional transcripts included IL32, CCL22, and CX3CR1. By contrast, CCR8 ICOS− Tregs expressed high amounts of transcripts encoding molecules associated with early differentiation or quiescence, including CCR7, KLF2, LEF1, TCF7 (29), BACH2 (repressing effector programs to stabilize Treg-mediated immune homeostasis, ref. 30), and TXNIP (a negative regulator of AKT signaling and glycolytic metabolism) (Figure 2B and Supplemental Table 3).

Gene set enrichment analysis (GSEA) further revealed that CCR8 ICOS+ Tregs were largely quiescent and displayed transcriptional signatures of Wnt/β-catenin and TGF-β signaling. In contrast, CCR8+ICOS− Tregs displayed enhanced signatures of metabolic activity, including oxidative phosphorylation and glycolysis; mTORC1-dependent activity, previously shown to favor murine Treg activation and prevention of autoimmunity (31); and reactive oxygen species metabolism, consistent with enhanced activation and/or mitochondrial respiration (Figure 2C, Supplemental Table 4, and ref. 32). To identify transcriptional regulators of CCR8+ICOS− intratumoral Tregs, we performed computational analysis of TF-binding motif enrichment at the promoters (~950, +50 bp from the TSS) of DEGs obtained from bulk RNA-seq data. This analysis showed enrichment of binding motifs of TFs, including IRF4, predicted to be preferentially active in the CCR8 ICOS− Treg subset (Figure 2D). We additionally identified NRfx1, involved in antioxidant defense, lipid metabolism, and mitochondrial respiratory function (33); MYC, a master regulator of metabolic reprogramming in activated T cells (34); and the NF-xB family members REL, RELA, and RELB. In particular, RelA has been previously shown to regulate effector Treg activity in nonlymphoid tissues downstream of TNFRSF5 (35). Thus, our transcriptional profiling revealed that intratumoral IRF4+ Tregs are highly activated compared with IRF4− Tregs and supported the notion that they have enhanced suppressive potential. To confirm this hypothesis, FACs-sorted CCR8+ICOS+ (IRF4+) and CCR8 ICOS− (IRF4−) intratumoral Tregs were further tested for their capacity to suppress proliferation of autologous CD4+CD25+ Tconv cells in vitro (Figure 2E). Both Treg subsets were effective in this regard at a 1:1 Tconv cell/Treg ratio, while only CCR8+ICOS+ Tregs maintained substantial suppressive capacity at a 2:1 ratio (Figure 2E).

IRF4 has been shown to promote effector Treg differentiation in peripheral tissues and to limit autoimmunity (20), but its importance in suppressing antitumor immune responses is unknown. To test the functional role of IRF4 in tumor-infiltrating Tregs, we used mice that allow tamoxifen-inducible deletion of IRF4 specifically in Tregs (Irf4fl/fl Foxp3EGFP-cre-ERT2) and controls (Foxp3EGFP-cre-ERT2) (Figure 2F). Induced deletion of Irf4 in Foxp3+ cells in MC38 tumor-bearing mice resulted in a significant delay in tumor growth (Figure 2F), indicating that IRF4+ Tregs suppress antitumor immunity. To further test the Treg-intrinsic role of IRF4, we reconstituted lethally irradiated mice with a mix of congenically marked bone marrow from WT mice and mice with a T cell–specific deletion of IRF4 (Irf4fl/flCd4cre). We also generated mixed control chimeras containing WT and Cd4cre control bone marrow. Flow cytometric analysis of tumor-infiltrating Tregs in these chimeric mice showed severely impaired representation of IRF4-deficient Tregs at the tumor site but not in the spleen and lack of ICOS expression, a direct target of IRF4. In contrast, control chimeras showed similar contribution of Tregs at both sites and robust ICOS expression (Supplemental Figure 2, E and F).

IRF4 and its partner BATF control a molecular program of effector Treg differentiation and suppression in tumors. Next, we formally tested the role of IRF4 and its transcriptional partner BATF in determining the features of tumor-infiltrating Tregs by integrating our data from human Tregs with gene expression profiles and epigenomic data from mouse Tregs (Supplemental Table 5). As mouse versus human gene regulation is difficult to infer due to species differences in noncoding regions, we first defined a conserved tumor-infiltrating Treg signature by integrating DEGs of CCR8+ICOS+ versus CCR8 ICOS− Tregs from Figure 2B and Supplemental Table 3 and DEGs of tumor-infiltrating Tregs versus spleen Tregs from a murine model (36), as outlined in Figure 3A. In total, we identified 382 transcripts that were specifically upregulated or downregulated in mouse and human tumor-infiltrating Tregs (Figure 3A and Supplemental Table 6). Next, we defined the transcriptional program that is dependent on IRF4 or BATF expression by performing RNA-seq and analysis of gene expression profiles of splenic Tregs from WT versus Irf4−/− mice. We also reanalyzed a published data set comparing WT versus Batf−/− Tregs (37). Overall, this identified 1241 and 232 genes that were controlled by IRF4 and BATF, respectively (Figure 3B and Supplemental Table 5). GSEA revealed that many genes involved in lymphocyte activation, proliferation, and differentiation were under the joint control of IRF4 and BATF; those involved in apoptosis were controlled by BATF alone; and those related to immunosuppression, i.e., IL-37– and IL-10–dependent signaling pathways, were under the control of IRF4 alone (Supplemental Figure 3B). A relevant proportion (94 genes; 24.6%) of the conserved tumor Treg signature between humans and mice was controlled by IRF4 and/or BATF (Figure 3B; IRF4 and BATF DEGs vs. tumor-infiltrating Treg signature: P = 1.1 × 10−14 and P = 3.3 × 10−14, respectively; hypergeometric test; data not shown). We further made use of our ChIP deep-sequencing (ChIP-seq) data to assess IRF4 occupancy at the loci of interest (Supplemental Table 7) and thus define a direct role of this TF in controlling gene expression in tumor-infiltrating Tregs. Supplemental Figure 3B shows the distribution of regions in the genome that are bound directly by IRF4 according to their distance from transcriptional start sites (TSSs) (see also Supplemental Table 7). Despite a small fraction mapped in promoter regions (0–1 Kb), the majority of IRF4-bound sites mapped to 10 to 100 Kb dis-
A

CCR8*ICOS* vs CCR8*ICOS* DEGs

Tumor-infiltrating Treg signature (382 transcripts)

Mouse MC38 Tumor Tregs vs Spleen Tregs (ref. 36)

B

Baf+ vs WT DEGs

Ir4+ vs WT DEGs

Intersection with IRF4 ChIP sequencing data

Tumor-infiltrating Treg signature

C

IRF4 dependent genes

Tigit
Clt4
Tnrsf1b
Ccr8
Ccr3
Tmem154
Il1r2
Atrx1
Tnrsf4
Il12rb1
Tnrsf8
Zbb32
Grg2
Sic2a19
Mki67
Cr5
Asbh
Map2k3
Fam110a
Ccr2
Creb3l2
Ctma1
Tnrsf18
Fuc2
Dusp16
Prelid2
Klf23
Ptg
Rm2
Aurkb

IRF4 & BATF dependent genes

Icos
Sbl11
Gfr
Ikzf2
Tnrsf9
Il1r1
Casp3
Gcnt1
Il18r1
Plekhs2
S100a4
Ploc8
s100a6
Figure 3. Ifr4 and its partner Batf directly and indirectly control a molecular program of effector Treg differentiation and suppression. (A) Identification of a shared gene expression signature between tumor-infiltrating human CCR8+ICOS+ Tregs versus CCR8-ICOS- Tregs and murine Tregs (36). (B) Venn diagram of the number of genes of the tumor-specific Treg signature obtained as in A that are differentially expressed in splenic Tregs from Batf−/− and Ifr4−/− mice. Genes controlled only by Batf (n = 10) were of limited interest and thus not further investigated. (C) List of tumor-infiltrating Treg genes that are dependent on the expression of Ifr4 or Ifr4 and Batf. All genes are induced, except for Plac8, which is repressed (indicated in light blue). Those genes directly controlled by Ifr4 binding to the genome, as obtained from ChIP-seq analysis of murine Tregs, are highlighted. Genomic binding of Ifr4 to the DNA for selected genes is depicted.

The Journal of Clinical Investigation
Figure 4. Abundance of CCR8/ICOS+ intratumoral Tregs is associated with multiple features of T cell exhaustion. (A) Experimental workflow. (B) Heatmaps of the relative expression, depicted as integrated MFI (iMFI: MFI × percentage of antigen expression) of markers (columns) in discrete CD4+ (left) and CD8+ (right) Phenograph clusters (rows). Tm, memory; Tcm, central memory; Tn, naive; Exh, exhausted; Act, activated; CTL, cytotoxic T lymphocyte. Tte, terminal effector. Data are further metaclustered to group subpopulations with similar immune-phenotypes. The median frequency of each Phenograph cluster in the different compartments is depicted by using Balloon plots. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001, tumor versus blood or versus normal tissue samples; 2-way ANOVA with Bonferroni’s post hoc test. (C) Correlogram showing Pearson correlation between frequencies of CD4+ (T4) and CD8+ (T8) Phenograph clusters in tumor samples from 45 patients with early-stage (I–III) non–small-cell lung cancer (NSCLC). Nonsignificant correlations (P value > 0.05) were left blank.

Discussion

Human tumors are often infiltrated by large numbers of CD4+ Tregs that display a highly activated phenotype and enhanced suppressive capacity compared with those present in the peripheral and the adjacent tumor-free tissues (15, 16). We have now shown that the transcriptional program associated with such activation and suppression in the TME is driven by the TF IRF4 in combination with its molecular partner BATF. Signals downstream of the TCR are likely involved in IRF4 induction (45), possibly suggesting that human Tregs suppress antitumor immunity in an antigen-specific way.

IRF4, previously linked to effector Treg differentiation in murine tissues in physiology (20), is now shown to control the formation of ICOS+ effector Tregs in the TME that, in turn, favor tumor growth in a mouse model of cancer. IRF4 controls gene expression of tumor-infiltrating Tregs both directly, by binding gene promoters or distal regulatory regions, and indirectly, by inducing the expression of additional transcriptional regulators, such as IκZF2 (Helios), which is required for Treg stability (28). IRF4 alone binds DNA poorly; however, binding is increased when IRF4 is part of a macromolecular complex involving AP-1 family members BATF, JUN, JUNB, or JUND, which recognize DNA motifs known as AP-1/IRF composite elements (AICEs) (21, 46). Although the regions bound by these TFs are largely overlapping, IRF4 and BATF also bind unique regions (21), which possibly explains why their deficiency has differential, specific effects on gene expression. We did not formally test whether BATF is responsible for the expression of specific genes by direct binding; however, additional computational investigations identified AICE motifs in the proximity of genes that are linked to effector Treg differentiation and function, including Ccr8, Icos, CItla4, Cxcr3, Il12rb1, Tnfrsf1b, and Tnfrsf8 (data not shown). In relation to this, JunB has recently been shown to control murine effector Treg differentiation in the lung and colon (47), while additional TFs, such as STAT3, may physically interact with c-Jun (48). STAT3 mRNA is upregulated and the STAT3 binding motif is enriched in IRF4+ Tregs compared with IRF4– Tregs (data not shown), which overall suggests that a complex range of molecular interactions is cooperating to shape the effector differentiation and enhanced suppressive activity of intratumoral Tregs.

Our study reveals an additional important aspect, namely that effector differentiation is not a feature of all intratumoral Tregs. Rather, a subset of these cells with increased expression of IRF4 is preferentially expanded in lung, liver, and melanoma tumors compared with the adjacent tumor-free tissues and peripheral blood, as revealed by scRNA-seq. These IRF4+ Tregs express high amounts of molecules associated with enhanced immunosuppression, have increased metabolic demand, and are phenotypically and transcriptionally distinct from the more quiescent IRF4– Tregs. Whereas in humans approximately 40% of Tregs express IRF4+, as detected by flow cytometry, deletion of Irf4 in mice results in the near-complete loss of Tregs in tumors, which possibly indicates that low levels of IRF4 are also present in CCR8 ICOS+ Tregs. An alternative hypothesis is that slow tumor development, as seen in humans, results in a balanced infiltration of fewer and more activated Tregs. In line with this, approximately 40% of Tregs infiltrating lung adenocarcinoma forming in the K-rasG12D autochthonous model (which better recapitulates of the physiology of lung adenocarcinoma) express the IL-33 receptor ST2 (encoded by Il3lr1) (49), a direct genomic target of IRF4 (Figure 3C). Similarly, a recent human study found that approximately 50% of breast cancer-infiltrating Tregs express CCR8 (50), thereby corroborating our results of Treg heterogeneity in the TME. Despite not reaching the capability of scRNA-seq in terms of number of parameters being measured, the high-dimensional flow cytometry used here investigates T cell phenotypes as a whole in a large cohort of patients compared with those recently investigated by scRNA-seq (25) and is thus capable of further defining the relationships between Treg subsets and other T cell populations within the TME. In this way, we revealed that IRF4+ Tregs positively correlate with multiple subsets of exhausted and activated CD4+ and CD8+ T cells and their abundance is associated both with relapse and poor overall survival in multiple human cancers. Therefore, deep immunophenotyping with improved and high-throughput single-cell technologies can pinpoint those subsets associated with slower tumor growth and favorable antitumor responses with enhanced precision. We anticipate that the simple addition of an effector Treg marker (e.g., IRF4, ICOS, or CCR8 or a TNFR superfamily member) to Foxp3 staining, as done by immunohistochemistry in immunoscore approaches (51), will improve the definition of patients with improved prognosis.

The identification of CD4+ Treg heterogeneity in the TME and, as a consequence, of a molecular program mastering the differentiation of those Tregs with enhanced suppressive capacity offers potentially novel opportunities to reverse immunosuppression while favoring antitumor immune responses. Depletion of Tregs has been tested in a number of preclinical approaches to promote
activation or downstream IRF4-dependent Treg activation would result in a similar scenario. This approach may be widely applicable, as our data show that IRF4-driven effector Treg differentiation is common to at least 3 human tumor types, i.e., lung cancer, hepatocellular carcinoma, and melanoma. Further definition of the antitumor responses (11–14); however, novel strategies interfering selectively with the activated effector Treg state are emerging as promising tools to boost effective antitumor immunity without resulting in overt autoimmunity due to the loss of peripheral tolerance (14, 52). We expect that targeting those signals leading to IRF4 activation or downstream IRF4-dependent Treg activation would result in a similar scenario. This approach may be widely applicable, as our data show that IRF4-driven effector Treg differentiation is common to at least 3 human tumor types, i.e., lung cancer, hepatocellular carcinoma, and melanoma. Further definition of the
molecular network orchestrating the suppressive capacity of intra-
tumoral Tregs and, most importantly, the identification of specific
players that are not active in antitumor-infiltrating lymphocytes is
anticipated to benefit cancer immunotherapy strategies.

Methods

Study design. The characteristics of the patients and of the samples
used in this study as well as the procedures of cell isolation have been
described previously (24). Details on the patients’ characteristics
included in this manuscript are further indicated in Supplemental Table
1. Information on the pathological stage, determined by an institutional
pathologist (some patients were restaged as III following examination
of the tumor), was available for all patients, while results of the preop-
erative FDG PET-CT scan were available for 25 patients. Details on
obtainment of PET scans have been described previously (24).

Polychromatic flow cytometry and cell sorting. Antibodies used
in the study are listed in Supplemental Table 2. Flow cytometry proce-
dures for high-dimensional single-cell panel development have been
described previously (24, 39). Additional panels used for further char-
acterizing the IRF4+ CD4+ cell subset are listed in Supplemental Table
2. All data were acquired on a FACS Symphony A5 flow cytometer (BD
Biosciences) equipped with 5 lasers (UV, 350 nm; violet, 405 nm; blue,
488 nm; yellow/green, 561 nm; red, 640 nm; all tuned at 100 mW,
except for UV, which tuned at 60 mW) and the capability of detecting 30
parameters. Flow cytometry data were compensated in FlowJo by
using single stained controls (BD Compbeads incubated with fluores-
cently conjugated antibodies), as described previously (53). CCR8+I-
COΣ- and CCR8 ICOS+ Tregs, pre gated as CD4+ Aqua+CD25+CD127+,
were isolated from tumor samples with a FACSARia cell sorter (BD
Biosciences). CCR8 and ICOS proved to be the best combination over
other markers to isolate Treg subsets with differential IRF4 expression
(data not shown).

Suppression of T cell proliferation by Tregs. Live (Aqua+) CD4+ CD25+
Tconv cells were isolated from patients’ blood samples with a FACSAr-
ia cell sorter and stained with a CellTrace CFSE kit (final concentra-
tion: 2 μM; Thermo Fisher Scientific) according to the manufacturer’s
protocol. Subsequently, cells were plated in R10 U-bottom 96-well
plates (10,000 cells/well) and stimulated with human Treg Suppres-
sion Inspector beads (Miltenyi Biotec) for 5 days at 37°C. Tconv cells
cultured alone, in the absence of bead stimulation, were used as non-
proliferating, negative control. CCR8+ICOS- and CCR8 ICOS+ Tregs
were FACS sorted from tumors and were added to autologous Tconv
cell cultures at different ratios (Tconv cells/Treg ratio = 1:1, 2:1, and
4:1). CFSE dilution was evaluated at day 5.

High-dimensional flow cytometry data analysis. Flow Cytometry
Standard (FCS) 3.0 files were imported into FlowJo software (version
9) and analyzed by standard gating to remove aggregates and dead
cells and identify CD3+CD4+ or CD8+ T cells. Three thousand CD4+
and CD8+ T cells per sample were subsequently imported in Flowjo
(version 10), biexponentially transformed, and exported for further
analysis in Python (version 3.7.3) by a custom-made pipeline of Phe-
noGraph (available here http://github.com/lugilah/CytoPhenograph,
where we modified the linux-community and the core.py script of
PhenoGraph package in order to fix the seed to “123456”). Blood,
adjacent lung tissue, and tumor samples were labeled with a unique
computational barcode for further identification and converted in
comma separated (CSV) files and concatenated in a single matrix by
using the merge function of pandas package. The K value, indicating
the number of nearest neighbors identified in the first iteration of
the algorithm, was set at 40 and 60 for CD4+ and CD8+ T cells clustering,
respectively. Clusters representing less than 1% of total CD4+ or CD8+
T cells were removed in subsequent analysis. The data were then reor-
ganized and saved as new CSV files, one for each cluster, that were
further analyzed in FlowJo to determine the frequency of positive cells
for each marker and the corresponding median fluorescent intensity
(MFI). These values were multiplied to derive the iMFI (rescaled to
values from 0 to 100; Figure 4B and refs. 24, 39) and then visualized in
a heatmap. Subsequent metaclustering of iMFI values was performed
using the gplots R package. Hierarchical metaclustering of all samples,
based on the frequency of PhenoGraph clusters (Figure 4B), was per-
formed in R according to the Ward minimum variance method. UMAP
was obtained by UMAP Python package and visualized in FlowJo 10.

Melanoma data set. Normalized scRNA-seq counts were retrieved
from the Gene Expression Omnibus (GEO GSE72056). Analysis was
restricted to the cells labeled as “T cells,” as previously defined by
Tirosh et al. (27). T cells were divided into CD4+ and CD8+, based on
the normalized expression levels (E) of CD4+ (E > 4) and CD8+ (average
of CD8A and CD8B, E > 4). Among all samples composing the data set,
466 were identified as CD4+ T cells. To assess which genes have the expres-
sion profile most correlated with that of IRF4, a Pearson correlation
coefficient, indicated as score in Supplemental Figure 1B, and a cor-
responding P value were computed between each gene expression
profile in the matrix (consisting of 23,686 genes) and IRF4. In order
to obtain the CD8 signature used in Supplemental Figure 5B, DEGs in
the pairwise comparison between CD8+ and CD4+ T cell subsets were
determined by the “FindAllMarkers” function coded in the Seurat R
package (version 2.3.4) with default parameters (54). In this way, we
obtained 225 specific genes for the CD8+ subpopulation respect to the
CD4+ T cells.

Lung and liver data sets. We took advantage of the web server for
exploration of NSCLC (http://lung.cancer-pku.cn) and hepatopo-
cellular carcinoma (http://hcc.cancer-pku.cn) single T cell RNA-seq
data to assess the expression levels of markers of interest within the
CD4+ intratumoral subpopulations. Lung and liver tumor-infiltrat-
ing CD8+ signatures (Figure 5D and Supplemental Figure 5A) were
obtained by combining all the DEGs from the CD8+ tissue-specific
clusters and by further excluding the circulating clusters labeled as
CD8+CT1-LEF1 (26, 27).

Mice. Irf4−/− mice (55) were originally provided by Tak Mak (Prin-
cess Margaret Cancer Centre, University Health Network, Toronto),
Irf4−/− mice crossed to Foxp3EGFP-Cre-ERT2 (JAX 016961) (56) were crossed to
Irf4−/− mice (JAX 009380) (57) to allow for specific deletion of Irf4 in Foxp3+ cells fol-
lowing tamoxifen treatment.

Mouse procedures. Mice were irradiated (2 × 5.5 Gy) and reconsti-
tuted by i.v. injection of 200 μL bone marrow isolated from femurs
and tibias of donor mice. Following irradiation mice were treated with
neomycin in drinking water for 4 weeks and allowed to recover for at
least 8 weeks. MC38 tumor cells (provided by Stephen Nutt, Walter
and Eliza Hall Institute of Medical Research, Melbourne, Victoria,
Australia) were grown in DMEM with 10% FCS and 1% PenStrep
(Gibco) in 37°C, 5% CO2 incubator and passaged every 2 to 3 days. For
tumor inoculation, 1 × 106 cells were resuspended in 100 μL PBS and
injected subcutaneously into the right flank of the mice. Tumor growth

The Journal of Clinical Investigation

Research Article

RESEARCH ARTICLE

jci.org   Volume 130   Number 6   June 2020

3147 JCI
was assessed with LCD Digital Vernier Calipers (Protech) every 2 to 3 days. Tamoxifen (2 mg/mouse) was administered in 200 μL sunflower oil i.p. for 5 consecutive days. Upon the experimental endpoint, mice were euthanized with CO₂ and cervical dislocation, and tumors were excised with forceps and scissors. Tumors were mechanically dissociated and digested in 1 mg/mL Collagenase IV (Gibco) in RPMI medium for 45 minutes at 37°C, with constant agitation.

**Treg isolation from mice.** Single-cell suspensions from spleens were enriched for CD4+ T cells by depleting CD8+ T cells and B cells using anti-CD8 and B220 antibodies. The CD4+ T cell–enriched cell suspension was stained with CD4 (RM 4-5) and TCR β anti-CD8 and B220 antibodies.

**Mouse RNA isolation and sequencing.** Mouse RNA was sequenced following the manufacturer’s protocol using the RNAeasy Plus Mini Kit (Qiagen). RNA from WT and Irf4−/− Tregs was sequenced using Illumina platform (75-bp paired-end reads).

**RNA-seq and bioinformatic analysis.** Mouse RNA isolations of the FACS-purified CCR8+ICOS+ and CCR8+ICOS− Tregs was performed following the manufacturer’s protocol using the Quick-RNA Micro Prep kit (Zymo Research). RNA quality control was performed with the Agilent 2200 Tape Station system, and only RNAs having a RIN >8 were used for library preparation. Libraries for mRNA sequencing were prepared starting from 1.5 ng total RNA for each sample by using the SMART-Seq v4 Ultra Low Input RNA Kit (Clontech-Takara). All samples were sequenced on an Illumina NextSeq500 at an average of 32.9 million 75-bp single-end reads. After quality control, raw reads were aligned to the human genome (GRCh38.12) using the STAR aligner with default parameters (version 2.7.0) (58). Gene-based read counts were then obtained using HTSeq count (version 0.11) and GENCODE v29.gtf annotation (60). The read counts were imported into R statistical software, and differential gene expression analysis was performed using the edgeR package (version 3.22) (61). For pair-wise comparisons, raw read counts were normalized using the TMM method (trimmed mean of log-ratio values) (62), and genes that failed to achieve a counts per million (CPM) mapped reads value greater than 1 in at least 2 libraries were not considered. P values were adjusted using the Benjamini-Hochberg method. Genes were considered differentially expressed when FDR < 0.05 and when they had an expression change of more than 1 log, fold change. The heatmap representing the log, of CPM was obtained using heatmap R package (version 1.0.12) with the distance method “correlation” for both rows and columns.

**Gene signature identification (RNA-seq).** GSEA was performed using GSEA (version 3.0) software (Broad Institute of MIT) and gene list ranked based on log, fold changes. The gene set enrichment analysis was conducted in preranked mode with scoring scheme “classic” and 1,000 permutations. The maximum gene set size was fixed at 5,000 genes, and the minimum size was fixed at 10 genes. The gene signature was retrieved from the H collection (h.all.v6.2.symbols.gmt) of the Molecular Signatures Database (MSigDB v6.2). The GSEA in Supplemental Figure 3B was performed with custom gene sets relevant to immunological signatures (https://github.com/ligulab/ProjectScripts_Treg_Irf4/blob/master/Figure3S/Mouse_ImmunePath_February_01_2019_symbol.gmt). The dot plot was generated with a custom Rscript (https://github.com/ligulab/ProjectScripts_Treg_Irf4/blob/master/Figure3S/ImmunoSignatureDotPlot.r).

**Motif enrichment analysis.** The PScan software tool (version 1.5) was used to perform the in silico computational analysis of overrepresented TF binding sites within the 5’-promoter regions of DEGs (63). PScan was run on [−950, +50] bp upstream regions onto the Homo sapiens JASPAR 2018 NR database (64). Results were summarized with a scatter plot, where P values were plotted against Z score on vertical axis by using the Python Matplotlib package (version 3.0.3).

**Bioinformatic analysis of microarray data.** Microarray probe fluorescence signals downloaded from the Gene Expression Omnibus (GEO GSE89656 and GSE61077, samples GSM1496276, GSM1496277, GSM1496274, GSM1496275) were converted to expression values using robust multiarray average procedure RMA (65) of the Bioconductor Affy package. Fluorescence intensities were background adjusted and normalized using quantile normalization, and expression values were calculated using median polish summarization and custom chip definition files for a total of 18,075 custom probe sets for Mouse Genome 430 2.0 Array based on Entrez genes (Mouse-4302_Mm_ENTREZG version 21.0.0) and 12,426 custom probe sets for Mouse Genome 430A 2.0 Array based on Entrez genes (Mouse-430A2_Mm_ENTREZG version 21.0.0). To identify genes that are differentially expressed, we compared the expression profiles of Batf−/− Tregs and WT Tregs, using limma algorithm coded in the same R package (66). All data analyses were performed in R (version 3.4.4) using Bioconductor libraries and R statistical packages.

**Bioinformatic analysis of ChIP-seq data.** Raw data were downloaded from the Gene Expression Omnibus (GEO GSE98264). Reads were aligned to mouse genome GRCh38.p6/mm10 using Bowtie2 (version 2.1.0) (67) in local alignment mode. After alignment to the reference genome, mitochondrial and ambiguously mapped reads were discarded with Samtools (68) and further used for sorting and indexing mapping files. Bigwig files for IGV (69) genome coverage visualization were generated with the multiBamSummary module from the deepTools suite (version 3.2.0) (70). To call peaks, we used MACS2 (version 2.1.2) (71) with these parameters: callpeak gsize mm nomodel extsize 147 and Qvalue 1 × 10−5. Peaks within 30 kb upstream and 10 kb downstream of the TSS or within intragenic regions were annotated with the closest TSS using ChIPSeeker (version 1.18.0) (72) and GENCODE M20.gtf gene annotation.

**Survival analysis.** Transcriptomic and clinical data of human lung adenocarcinoma, hepatocellular carcinoma, and melanoma from TCGA database (provisional cohorts) were obtained from the cbioPortal platform. Signatures of CCR8 ICOS+ Tregs (Figure 2B) and CD8+ T cells (see “Gene signature identification”) were used to calculate patient-specific enrichment scores from specimens of lung adenocarcinoma (LUAD), hepatocellular carcinoma (LIHC) and melanoma (SKCM) data sets (“GSVA” R package) (73). Survival curves were calculated between groups of patients subdivided according to the percentile rank (set at 0.8) of the resulting scores. The R packages “survival” (http://cran.rproject.org/web/packages/survival/index.html) and “survminer” (http://cran.r-project.org/web/packages/survminer/index.html) were used to assess statistics and obtain survival curves.

**Data availability.** The gene expression data generated in this study are available in the GEO database (GSE128822).

**Statistics.** Statistical analyses were performed using GraphPad Prism (version 7), unless specified otherwise. Data were first tested for normal distribution with D’Agostino-Pearson, Shapiro-Wilk, or Kolmogorov-Smirnov normality tests and then analyzed with Student’s t
test (paired, 2 tailed), Wilcoxon rank test (paired nonparametric data), or Mann-Whitney (unpaired nonparametric data) when comparing 2 groups or Friedman test or 2-way ANOVA with Bonferroni’s post hoc test for multiple comparisons when comparing 3 groups (specific tests are specified in the figure legends).

Correlation of gene expression from scRNA-seq data was determined by calculating the Pearson correlation coefficient. P values of less than or equal to 0.05 were considered significant. PCA was performed by the prcomp function of the R stats package. Hypergeometric tests between Irf4 or Batf DEGs or scRNA-seq signature (25) and the murine tumor-infiltrating Treg signature (Figure 3B) were run with GeneOverlap R package.

Study approval. All human experiments were approved by the Humanitas Clinical and Research Center Internal Review Board (approval 1501). All patients provided written informed consent. All mice were maintained and used in accordance with the guidelines of the University of Melbourne Animal Ethics Committee.

Author contributions
GA, J. Brummelman, SP, EMCM, EPT, CP, AV, and J. Blume performed experiments. FSC provided expertise with cell sorting. VZ, CP, and AS provided technical support. MA, PN, and GV performed surgery. AL, E. Lopci, and GV provided clinical information and helped with clinical interpretation of the data. RR, MK, and MP provided expertise in data analysis. GA, J. Brummelman, SP, AK, and E. Lugli conceived the study. E. Lugli supervised the study and GA and E. Lugli wrote the paper. All authors edited the paper. GA, J. Brummelman, and SP share first authorship. GA and J. Brummelman provided equal contribution in conceiving the overall study and in performing the vast majority of the experiments, while SP conceived and performed all the bioinformatic analyses. Given the importance of bioinformatics in this manuscript, these authors deserve equal contribution. The order of the first authors reflects the leadership exerted in the study.

Acknowledgments
We wish to thank Elisa Dieci (Humanitas Clinical and Research Center) for helping with patients’ information, Gianluca Rotta and Jens Fleischer (BD Biosciences) for helping with FACSymphony A5 instrument setup, as well as Silvia Piconese (University of Rome La Sapienza), Gioacchino Natoli (European Institute of Oncology), and the members of the Laboratory of Translational Immunology for critical discussion. This work has been supported by grants from the Associazione Italiana per la Ricerca sul Cancro (investigator grant 20676 to E. Lugli and My First AIRC Grant 189323 to E. Lugli), Bristol-Myers Squibb (preclinical grant CA209-9YM to E. Lugli), and the Humanitas Clinical and Research Center. J. Brummelman is a recipient of the “Fondo di beneficenza Intesa San Paolo” fellowship from AIRC. EMCM and PN are recipients of the 2017 Fondazione Umberto Veronesi postdoctoral fellowship. Purchase of the BD FACSymphony A5 has been in part defrayed by a grant from Italian Ministry of Health (agreement 82/2015). AK is supported by grants and a fellowship from the National Health and Medical Research Council of Australia. J. Blume was supported by a fellowship from the Deutsche Forschungsgemeinschaft.

Address correspondence to: Enrico Lugli, Via Manzoni 56, 20089, Rozzano, Italy. Phone: 39.02.8224.5143; Email: enrico.lugli@humanitasresearch.it.